Incyte Corporation (INCY) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

17/25

Growth 5 Margin 1 Expansion 5 Platform 1 Financial 5

latest quarter score

Earnings Reports

17
Incyte (INCY) Q2 2026: Core Business Ex-Jakafi Up 44%, Pipeline and Launches Diversify Growth
July 28, 2026
19
Incyte (INCY) Q4 2025: Core Business Ex-Jakafi Jumps 53% as Pipeline Drives 2026 Inflection
June 16, 2026
20
Insight (INCY) Q1 2026: Core Portfolio Ex-Jakafi Jumps 63%, Accelerating HemOnc & I&I Transition
April 28, 2026
21
Incyte (INCY) Q3 2025: Product Revenue Climbs 19% as Pipeline Pruning Sharpens Focus on Next-Decade Growth
October 28, 2025
19
Incyte (INCY) Q2 2025: Opsalura Surges 35% as Pipeline Execution Drives Guidance Raise
July 29, 2025
22
Incyte (INCY) Q1 2025: JAKAFI Surges 24% as Pipeline Milestones Set Up Multi-Launch Year
July 06, 2025

Browse all companies